Testosterone Replacement Therapy for Younger Men

Clinical trial evidence evaluating testosterone replacement therapy was established almost exclusively in older men, leaving prospective efficacy and safety unstudied in men in their 20s and 30s.

At Longevity Benchmark, we review clinical endocrine guidelines and biomarker research to help readers separate physiological evidence from commercial marketing claims.

Clinical Trial Limitations and the Evidence Gap for Young Men

No large randomized trial of long-term testosterone safety has enrolled a man under 45. The TRAVERSE trial, published in the New England Journal of Medicine in 2023, enrolled 5,246 men aged 45 to 80 with cardiovascular risk factors, while the earlier Testosterone Trials enrolled participants aged 65 and older. No comparable randomized, placebo-controlled trial exists for men in their 20s or 30s.

The Endocrine Society clinical practice guideline explicitly notes that most studies of testosterone therapy in young hypogonadal men were open-label cohorts that lacked placebo control groups. Long-term safety outcomes beyond five years regarding cardiovascular health, metabolic function, prostate tissue, and spermatogenic recovery in men under 40 remain completely unmeasured in prospective trials.

Regulatory approvals reflect this boundary. The current Food and Drug Administration prescribing information for AndroGel 1% restricts its indication to primary and hypogonadotropic hypogonadism resulting from documented structural or genetic medical conditions. The label states that safety and efficacy have not been established in age-related hypogonadism or in patients under 18 years of age. Our review of testosterone replacement therapy side effects and risks outlines how risk profiles shift across age groups.

Diurnal Hormone Swings and the Morning Testing Requirement

Diurnal variation in circulating testosterone levels is substantially wider in young men than in older adults. Research by Brambilla and colleagues published in The Journal of Clinical Endocrinology & Metabolism demonstrated that men aged 30 to 40 experience a 20% to 25% drop in total testosterone between 08:00 and 16:00, whereas men aged 70 experience only a 10% decline over the same interval.

Afternoon blood draws represent a primary cause of false-positive biochemical deficiency. In the Brambilla trial, seventeen men who recorded afternoon measurements below 300 ng/dL had completely normal testosterone concentrations across all three of their morning visits, including five out of eight men in the 30 to 47 age group. An afternoon test captures a normal physiological trough rather than pathological endocrine failure.

Day-to-day biological variability also creates substantial diagnostic noise. A related study by the same group established that two separate measurements in the same person differ by more than 18% to 28% about half the time. Clinical guidelines require confirming any low total testosterone reading with a second early morning draw before assigning a diagnosis. Detailed draw logistics are covered in our guide to free versus total testosterone.

Diagnostic Threshold Disagreements Across Major Guidelines

The leading clinical endocrine organizations disagree on the exact numerical cut-off defining biochemical testosterone deficiency. The American Urological Association guideline on testosterone deficiency establishes a total testosterone level below 300 ng/dL as a reasonable threshold supporting a diagnosis when combined with symptoms. In contrast, the Endocrine Society guideline establishes 264 ng/dL as the lower limit of normal.

This disagreement creates a 36 ng/dL grey zone where a young man can be categorized as deficient by urological criteria yet biochemically normal by endocrine criteria. The Endocrine Society threshold is derived from research by Travison and colleagues, who harmonized reference ranges from 9,054 men across four international cohorts all cross-calibrated to one national reference method. For healthy, non-obese men aged 19 to 39, the harmonized 2.5th to 97.5th percentile range spanned 264 to 916 ng/dL, with a median of 531 ng/dL.

Travison and co-authors also noted that a substantial proportion of variation between cohorts stemmed from differences in laboratory assay methodology rather than patient biology. The Endocrine Society advises against using direct analog-based free testosterone immunoassays due to documented analytical inaccuracies, recommending calculated free testosterone or equilibrium dialysis instead.

Functional Causes and Secondary Suppression in Young Adults

Testosterone suppression in young men is predominantly functional and potentially reversible rather than permanent testicular failure. Table 1 of the Endocrine Society guideline separates organic hypogonadism, which stems from congenital, structural, or destructive conditions, from functional hypogonadism, which results from external factors that suppress gonadotropin signaling.

Functional suppressors include severe caloric restriction, excessive endurance training, chronic opioid exposure, glucocorticoid medication, systemic illness, sleep disruption, and significant adiposity. A systematic review and meta-analysis by Corona and colleagues in the European Journal of Endocrinology showed that both low-calorie diets and bariatric surgery produce statistically significant increases in total testosterone. The androgen rise was more pronounced in younger, non-diabetic subjects with higher initial degrees of obesity.

True organic primary hypogonadism in young men is frequently genetic, with Klinefelter syndrome being the most common variant. An epidemiological study by Bojesen and colleagues found that while Klinefelter syndrome occurs in 153 to 213 per 100,000 male fetuses, only roughly 40 per 100,000 adult men are ever diagnosed. Fewer than 10% of cases are identified before puberty, meaning adult hypogonadism investigations are often the point of detection. When severe oligospermia or azoospermia is present, the American Urological Association recommends genetic karyotyping.

Endocrine Disruption from Prior Anabolic Steroid Use

Prior use of anabolic-androgenic steroids represents a distinct, age-relevant cause of persistent secondary hypogonadism that routinely escapes medical disclosure. A case-control study by Rasmussen and colleagues in PLOS ONE evaluated recreational strength trainers aged 18 to 50 who had discontinued anabolic steroids for an average of 2.5 years. Former users exhibited significantly lower median total testosterone levels compared to non-user controls, recorded at 14.4 nmol/L versus 18.8 nmol/L.

In that study, 27.2% of former users remained below the normal reference limit of 12.1 nmol/L years after cessation, compared to 0% of controls. Former steroid users also reported elevated rates of depressive symptoms at 24.2%, erectile dysfunction at 27.3%, and reduced libido at 40.1%. Current users exhibited severely suppressed levels of anti-Mullerian hormone and inhibin B, indicating compromised spermatogenesis.

Relying on standard blood testing can create diagnostic confusion. Section 5.6 of the AndroGel 1% prescribing information notes that men abusing synthetic testosterone derivatives can show suppressed endogenous production while blood testosterone levels test within the normal or subnormal range. Furthermore, survey research by Grant and colleagues from Imperial College London found that while 56.5% of men who discontinued anabolic steroids used post-cycle therapy regimens containing gonadotropins or estrogen modulators, objective evidence that these protocols reduce the duration or severity of hypogonadal withdrawal is lacking.

Pituitary and Testicular Evaluation Through Gonadotropin Panels

A total testosterone measurement alone cannot distinguish whether hormone deficiency originates in the testes or the pituitary gland. Recommendation 1.3 of the Endocrine Society guideline instructs clinicians to measure serum luteinizing hormone and follicle-stimulating hormone to separate primary from secondary hypogonadism. AUA Statement 6 goes only as far as luteinizing hormone, and its Statement 10 adds follicle-stimulating hormone for men interested in fertility.

Primary hypogonadism features elevated gonadotropins alongside low testosterone, signaling that the pituitary is attempting to stimulate damaged Leydig cells. Secondary hypogonadism features low or inappropriately normal gonadotropins, pointing to pituitary or hypothalamic suppression. American Urological Association Statement 7 directs clinicians to measure serum prolactin whenever low testosterone is paired with low or normal luteinizing hormone, because elevated prolactin can indicate a pituitary adenoma.

This biological distinction determines clinical management. In secondary hypogonadism, spermatogenesis can often be stimulated and fertility preserved using gonadotropic signaling agents. In primary testicular failure, the testes are physically incapable of responding to hormonal stimulation, restricting reproductive options to donor sperm or assisted reproductive technologies. Our breakdown of the male hormone panel details how these pituitary markers interact.

Spermatogenic Suppression and Fertility Recovery Odds

Exogenous testosterone administration delivers negative feedback to the hypothalamus and pituitary, shutting down endogenous follicle-stimulating hormone and luteinizing hormone production. The AndroGel 1% prescribing information states that exogenous androgens suppress pituitary gonadotropins, which leads to reduced sperm count and azoospermia. Intratesticular testosterone falls drastically, arresting sperm maturation.

Suppression occurs rapidly. In research by Anderson and Wu, a significant decline in luteinizing hormone was detectable within 24 hours of starting testosterone injections, with gonadotropins falling below assay detection limits by 12 weeks. Complete cessation of sperm production is common but variable. In a landmark trial by the World Health Organization Task Force on Methods for the Regulation of Male Fertility, 200 mg weekly testosterone enanthate induced azoospermia in 66.7% of non-Asian men and 89.2% of Asian men by six months.

Disagreement exists regarding whether fertility recovery after stopping therapy is universal or permanently impaired. A pooled analysis by Liu and colleagues in The Lancet, analyzing 1,549 men across 30 contraceptive studies, concluded that sperm recovery reached 100% within 24 months. Conversely, the official FDA label for AndroGel 1% warns that reduced fertility and testicular atrophy may be irreversible. The discrepancy reflects the study populations: Liu evaluated healthy, fertile men on supervised, time-limited contraceptive regimens, whereas regulatory warnings encompass clinic patients with baseline subfertility and individuals with prolonged exposure. The American Urological Association guideline notes that 10% of men in contraceptive trials had not recovered sperm by the end of the first year after cessation. No recovery figure here was measured in a young man taking testosterone for diagnosed hypogonadism. Every one comes from healthy eugonadal contraceptive volunteers, a different population from a 28-year-old on open-ended therapy, and no study has measured the second group.

Clinical Evidence for Fertility-Sparing Medications

Clinicians managing young men seeking to preserve fertility frequently look to non-testosterone medications to stimulate endogenous production. Statement 27 of the American Urological Association guideline states that clinicians may consider aromatase inhibitors, human chorionic gonadotropin, selective estrogen receptor modulators, or combinations thereof in symptomatic men desiring fertility maintenance. However, this is assigned a Grade C recommendation, reflecting the lowest tier of evidence.

Human chorionic gonadotropin acts as an analog to luteinizing hormone, maintaining intratesticular testosterone synthesis. Evidence for combining it with testosterone relies heavily on small, uncontrolled trials. A retrospective study by Hsieh and colleagues in The Journal of Urology followed 26 men taking testosterone alongside 500 IU of human chorionic gonadotropin every other day. Over an average follow-up of 6.2 months, no patient became azoospermic and nine men achieved pregnancy, but the trial lacked a control group or randomization.

Selective estrogen receptor modulators block estrogen feedback at the pituitary, stimulating natural gonadotropin release. In phase III randomized trials published by Kim and colleagues in BJU International, enclomiphene citrate raised testosterone while maintaining normal sperm concentrations and increasing gonadotropins over 16 weeks, contrasting with significant suppression in the topical testosterone group. Our comparison of enclomiphene versus TRT analyzes that mechanism in detail.

Regulatory approval does not match clinical practice patterns. Per the Pregnyl FDA label on DailyMed, human chorionic gonadotropin is approved specifically for hypogonadotropic hypogonadism, not for co-administration with testosterone to protect fertility. Enclomiphene citrate has never received FDA approval, and aromatase inhibitors carry no regulatory indication for male hypogonadism. A review by McBride and Coward emphasized that off-label use of these compounds to recover spermatogenesis remains poorly characterized in medical literature.

Prescriptions Up Fourfold in Men 18 to 45

Prescription rates for testosterone replacement therapy have expanded fastest among younger demographics. Claims data analyzed by Rao and colleagues in The Journal of Urology showed a fourfold increase in testosterone use among men aged 18 to 45 between 2003 and 2013, rising from 29.2 to 118.1 per 10,000 person-years. More recently, national prescription monitoring data published by Selinger and Thallapureddy in PLOS ONE documented a 120% increase in testosterone prevalence among patients aged 24 and under between 2018 and 2022, alongside an 86% increase in men aged 25 to 34.

This rapid clinical adoption occurs alongside documented gaps in baseline diagnostic rigor. A large study by Baillargeon and colleagues found that 19.5% of men initiating testosterone did not meet laboratory criteria for low testosterone prior to starting, and nearly half had no follow-up blood test in the subsequent year. However, that screening cohort was restricted to men aged 40 and older, meaning comprehensive, published diagnostic compliance data for men in their 20s and 30s remains completely unavailable.

Regulatory evaluations of cardiovascular risk have diverged over time across major bodies. The 2018 American Urological Association guideline states that clinical evidence cannot definitively determine whether testosterone increases or decreases cardiovascular event risks. In February 2025, the FDA issued a class-wide labeling change removing the cardiovascular risk warning from the Boxed Warning based on findings from the TRAVERSE trial, while requiring updated warnings regarding blood pressure elevations. Earlier, the European Medicines Agency Pharmacovigilance Risk Assessment Committee concluded in 2014 that available data did not confirm an increased heart risk in men with genuine testosterone deficiency.

Who This Does Not Apply To

Starting testosterone therapy is explicitly advised against for men who are actively attempting to conceive or planning near-term fatherhood. Recommendation 2.2 of the Endocrine Society guideline and Statement 23 of the American Urological Association guideline both advise against prescribing testosterone to men seeking immediate or near-term fertility. For those navigating reproductive planning, our full guide to TRT and fertility covers alternative clinical protocols.

Testosterone therapy is also not appropriate for men who have only obtained a single non-fasting or afternoon blood draw, or those whose fatigue, low libido, or weight gain stem from untreated obstructive sleep apnea, severe caloric restriction, or chronic stress. AUA Statement 21 directs clinicians to counsel every man with testosterone deficiency on weight loss and physical activity, which the guideline says has the potential to raise total testosterone on its own. Identifying non-hormonal contributors is covered in our analysis of signs of low testosterone.

What would change our answer: a multi-year, randomized, placebo-controlled trial enrolling men aged 18 to 39 that measures major cardiovascular events, metabolic adaptations, and long-term fertility recovery. Until prospective data in younger cohorts demonstrates clear clinical superiority and predictable fertility restoration, the evidence base supporting testosterone therapy remains an extrapolation from older men. What the guidelines describe as an adequate workup is two separate early-morning fasting total testosterone measurements on an accuracy-certified assay, with serum luteinizing hormone alongside them to separate a testicular cause from a pituitary one.

Related

• TRT after 50
• Testosterone replacement therapy and male fertility
• Clinical signs and symptoms of low testosterone
• Enclomiphene versus testosterone replacement therapy
• Free versus total testosterone testing guide
• Comprehensive male hormone blood panel guide
• Testosterone replacement therapy risks and side effects